Eko Health announces large-scale deployment of AI heart disease detection technology

Eko, a leading AI health technology company, has secured regulatory approval with the UKCA marking for its innovative AI-enabled technology. This development is part of the TRICORDER program, spearheaded by researchers at Imperial College London and supported by the National Institute for Health Research (NIHR). The program's primary goal is to introduce Eko's AI technology to 100 primary care practices across the United Kingdom.

Eko's AI-driven solution represents a significant leap forward in cardiac health assessment. It enables non-invasive cardiac examinations that effectively detect heart conditions such as heart failure, valvular heart disease, and atrial fibrillation. These early detections are pivotal for reducing healthcare costs associated with emergency admissions for heart failure, which is both common and costly.

At the heart of Eko's AI technology is a digital stethoscope and a user-friendly app that empowers healthcare professionals to conduct comprehensive cardiac assessments during routine patient visits. When the AI algorithms identify potential cardiac issues, healthcare providers can promptly initiate further diagnostic tests and potentially life-saving interventions. The program aims to address the critical need for early diagnosis in heart conditions, offering a promising solution to improve patient outcomes and reduce healthcare costs.

Dr. Nicholas Peters, a Professor of Cardiology at Imperial College London and the clinical-academic implementation team lead, emphasises the critical importance of early diagnosis in heart conditions. He notes that a significant proportion of heart failure diagnoses in the UK occur during emergency admissions, costing over £2 billion in annual healthcare expenses. Eko's AI technology has the potential to substantially alleviate this financial burden by potentially saving up to £2,400 per patient through the reduction of emergency room visits.